Cargando…

The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)

INTRODUCTION: The benefits of rotavirus (RV) vaccination in developed countries have focused on reductions in mortality, hospitalization and medical visits, and herd protection. We investigated other aspects related to RV-induced nosocomial infection, duration of hospital stay, age shift, and sustai...

Descripción completa

Detalles Bibliográficos
Autores principales: Standaert, Baudouin, Strens, Danielle, Li, Xiao, Schecroun, Nadia, Raes, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125134/
https://www.ncbi.nlm.nih.gov/pubmed/27714677
http://dx.doi.org/10.1007/s40121-016-0131-0
_version_ 1782469937683496960
author Standaert, Baudouin
Strens, Danielle
Li, Xiao
Schecroun, Nadia
Raes, Marc
author_facet Standaert, Baudouin
Strens, Danielle
Li, Xiao
Schecroun, Nadia
Raes, Marc
author_sort Standaert, Baudouin
collection PubMed
description INTRODUCTION: The benefits of rotavirus (RV) vaccination in developed countries have focused on reductions in mortality, hospitalization and medical visits, and herd protection. We investigated other aspects related to RV-induced nosocomial infection, duration of hospital stay, age shift, and sustained vaccine impact (VI) over time. METHOD: RotaBIS (Rotavirus Belgian Impact Study; ClinicalTrials.gov identifier, NCT01563146) annually collects retrospective data on hospitalization linked to RV testing in children up to 5 years old from 11 pediatric wards located all over Belgium. Data from 2005 to 2012 have been split in pre- (2005–2006) and post-vaccination (2007–2012) period. Information was collected on age, gender, RV test result, nosocomial infection caused by RV and duration of hospital stay. RESULTS: Over the 6-year period after the introduction of the RV vaccine, an 85% reduction in nosocomial infections was observed (221 in 2005 to 33 in 2012, p < 0.001). A significant reduction of almost 2 days in average duration of hospital stay per event was observed overall (7.62 days in 2005 to 5.77 days in 2012, p < 0.001). The difference is mainly explained by the higher reduction in number of nosocomial infections. A pronounced age shift (+24%, p < 0.01) of RV nosocomial infection to infants ≤2 months old was observed, increasing with length of post-vaccination period. VI was maintained over the follow-up (±79% VI per birth cohort). A decrease was seen depending on age, 85% (95% CI 76–91%) in the youngest to 63% (95% CI 22–92%) in the oldest age group. CONCLUSION: The higher reduction in nosocomial infection may affect the overall average duration of hospital stay for RV infection. No change in VI by birth cohort, but a reduction by age group was observed. These findings could be important for decision-makers considering the introduction of universal mass RV vaccination programs. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01563146. FUNDING: GlaxoSmithKline Biologicals SA (Rixensart, Belgium).
format Online
Article
Text
id pubmed-5125134
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51251342016-12-13 The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012) Standaert, Baudouin Strens, Danielle Li, Xiao Schecroun, Nadia Raes, Marc Infect Dis Ther Original Research INTRODUCTION: The benefits of rotavirus (RV) vaccination in developed countries have focused on reductions in mortality, hospitalization and medical visits, and herd protection. We investigated other aspects related to RV-induced nosocomial infection, duration of hospital stay, age shift, and sustained vaccine impact (VI) over time. METHOD: RotaBIS (Rotavirus Belgian Impact Study; ClinicalTrials.gov identifier, NCT01563146) annually collects retrospective data on hospitalization linked to RV testing in children up to 5 years old from 11 pediatric wards located all over Belgium. Data from 2005 to 2012 have been split in pre- (2005–2006) and post-vaccination (2007–2012) period. Information was collected on age, gender, RV test result, nosocomial infection caused by RV and duration of hospital stay. RESULTS: Over the 6-year period after the introduction of the RV vaccine, an 85% reduction in nosocomial infections was observed (221 in 2005 to 33 in 2012, p < 0.001). A significant reduction of almost 2 days in average duration of hospital stay per event was observed overall (7.62 days in 2005 to 5.77 days in 2012, p < 0.001). The difference is mainly explained by the higher reduction in number of nosocomial infections. A pronounced age shift (+24%, p < 0.01) of RV nosocomial infection to infants ≤2 months old was observed, increasing with length of post-vaccination period. VI was maintained over the follow-up (±79% VI per birth cohort). A decrease was seen depending on age, 85% (95% CI 76–91%) in the youngest to 63% (95% CI 22–92%) in the oldest age group. CONCLUSION: The higher reduction in nosocomial infection may affect the overall average duration of hospital stay for RV infection. No change in VI by birth cohort, but a reduction by age group was observed. These findings could be important for decision-makers considering the introduction of universal mass RV vaccination programs. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01563146. FUNDING: GlaxoSmithKline Biologicals SA (Rixensart, Belgium). Springer Healthcare 2016-10-06 2016-12 /pmc/articles/PMC5125134/ /pubmed/27714677 http://dx.doi.org/10.1007/s40121-016-0131-0 Text en © GSK group of companies, D. Strens and M. Raes 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Standaert, Baudouin
Strens, Danielle
Li, Xiao
Schecroun, Nadia
Raes, Marc
The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title_full The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title_fullStr The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title_full_unstemmed The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title_short The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012)
title_sort sustained rotavirus vaccination impact on nosocomial infection, duration of hospital stay, and age: the rotabis study (2005–2012)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125134/
https://www.ncbi.nlm.nih.gov/pubmed/27714677
http://dx.doi.org/10.1007/s40121-016-0131-0
work_keys_str_mv AT standaertbaudouin thesustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT strensdanielle thesustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT lixiao thesustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT schecrounnadia thesustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT raesmarc thesustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT standaertbaudouin sustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT strensdanielle sustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT lixiao sustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT schecrounnadia sustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012
AT raesmarc sustainedrotavirusvaccinationimpactonnosocomialinfectiondurationofhospitalstayandagetherotabisstudy20052012